Actively Recruiting
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
Led by Hamilton Health Sciences Corporation · Updated on 2026-03-12
120
Participants Needed
17
Research Sites
118 weeks
Total Duration
On this page
Sponsors
H
Hamilton Health Sciences Corporation
Lead Sponsor
C
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.
CONDITIONS
Official Title
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a pathogenic or likely pathogenic desmosomal gene variant (PKP2, DSG2, DSC2, DSP, or JUP) or the TMEM43-p.S358L variant (JUP carriers must be homozygous or compound heterozygous)
- Have an average of 500 or more premature ventricular contractions (PVCs) per 24 hours on a baseline 7-day Holter monitor
- Have a clinical diagnosis of arrhythmogenic cardiomyopathy or be a recognized genetic carrier for at least 6 months before screening
You will not qualify if you...
- Have New York Heart Association (NYHA) class IV heart failure
- Have ventricular scar due to coronary artery disease
- Have started, stopped, or changed dose of Class I or III anti-arrhythmic drugs within 3 months before screening
- Have any chronic liver disease that may be harmful
- Have alanine aminotransferase (ALT) levels more than twice the normal limit at screening
- Have total bilirubin above the normal limit at screening unless diagnosed with Gilbert's syndrome, in which case bilirubin must not exceed twice the normal limit
- Have a history of alcohol or illicit substance use disorders
- Use strong CYP3A4 inhibitors regularly and long-term (e.g., clarithromycin, ketoconazole, ritonavir)
- Have serum creatinine above 150 micromole/L or creatinine clearance 60 mL/min or below at screening
- Are pregnant or a woman of childbearing age not using highly effective contraception
- Are a male sexually active with a female of childbearing potential and not using acceptable contraception if not surgically sterile
- Are unwilling to provide informed consent or comply with follow-up
- Have hypersensitivity to tideglusib or its components, including strawberry allergy
- Use drugs metabolized by CYP3A4 with a narrow therapeutic window such as warfarin or digoxin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 17 locations
1
University of Calgary
Calgary, Alberta, Canada, T2N 2T9
Actively Recruiting
2
University of British Columbia
Vancouver, British Columbia, Canada, V6Z 1Y6
Actively Recruiting
3
Victoria Cardiac Arrhythmia Trials Inc.
Victoria, British Columbia, Canada, V8Z 0B9
Actively Recruiting
4
NL Health Services
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
Actively Recruiting
5
Nova Scotia Health
Halifax, Nova Scotia, Canada, B3H 2Y9
Actively Recruiting
6
Hamilton General Hospital
Hamilton, Ontario, Canada, L8L 2X2
Actively Recruiting
7
Kingston General Hospital
Kingston, Ontario, Canada, K7L 2V7
Not Yet Recruiting
8
London Health Sciences Centre
London, Ontario, Canada, N6A 5A5
Actively Recruiting
9
Newmarket Electrophysiologist Research Group 'NERG'
Newmarket, Ontario, Canada, L3Y 2P9
Not Yet Recruiting
10
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7
Not Yet Recruiting
11
Heart Health Institute Research Inc
Scarborough Village, Ontario, Canada, M1E 4B9
Actively Recruiting
12
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Not Yet Recruiting
13
St. Michael's Hospital
Toronto, Ontario, Canada, M5B 1W8
Not Yet Recruiting
14
Montreal Heart Institute
Montreal, Quebec, Canada, H1T 1C8
Actively Recruiting
15
McGill University Health Centre
Montreal, Quebec, Canada, H4A 3J1
Not Yet Recruiting
16
Hopital du Sacré-Coeur de Montréal
Montreal, Quebec, Canada, H4J 1C5
Not Yet Recruiting
17
University Institute of Cardiology and Pneumology of Quebec
Québec, Quebec, Canada, G1V 4G5
Actively Recruiting
Research Team
J
Jason Roberts, MD MAS
CONTACT
M
Maha Mushtaha
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here